ZA200500726B - Use of erythropoietin - Google Patents

Use of erythropoietin

Info

Publication number
ZA200500726B
ZA200500726B ZA200500726A ZA200500726A ZA200500726B ZA 200500726 B ZA200500726 B ZA 200500726B ZA 200500726 A ZA200500726 A ZA 200500726A ZA 200500726 A ZA200500726 A ZA 200500726A ZA 200500726 B ZA200500726 B ZA 200500726B
Authority
ZA
South Africa
Prior art keywords
epo
tissue
endothelial
derivatives
stimulating
Prior art date
Application number
ZA200500726A
Other languages
English (en)
Inventor
Ferdinand H Bahlmann
Hermann Haller
Original Assignee
Epoplus Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epoplus Gmbh & Co Kg filed Critical Epoplus Gmbh & Co Kg
Publication of ZA200500726B publication Critical patent/ZA200500726B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200500726A 2002-07-26 2005-01-25 Use of erythropoietin ZA200500726B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10234192A DE10234192B4 (de) 2002-07-26 2002-07-26 Verwendung von Erythropoetin

Publications (1)

Publication Number Publication Date
ZA200500726B true ZA200500726B (en) 2006-06-28

Family

ID=30128436

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200500726A ZA200500726B (en) 2002-07-26 2005-01-25 Use of erythropoietin

Country Status (26)

Country Link
US (4) US7745387B2 (enExample)
EP (3) EP1526867B1 (enExample)
JP (4) JP4727988B2 (enExample)
KR (2) KR20100077033A (enExample)
CN (3) CN101099731B (enExample)
AT (2) ATE360436T1 (enExample)
AU (2) AU2003255290B2 (enExample)
BR (1) BR0312981A (enExample)
CA (2) CA2710100A1 (enExample)
CY (2) CY1108052T1 (enExample)
DE (3) DE10234192B4 (enExample)
DK (2) DK1779862T3 (enExample)
EA (3) EA013966B1 (enExample)
ES (2) ES2345673T3 (enExample)
HR (3) HRP20100187A2 (enExample)
IL (2) IL166401A0 (enExample)
IS (3) IS2671B (enExample)
MX (1) MXPA05001120A (enExample)
NO (1) NO20051002L (enExample)
PL (2) PL395151A1 (enExample)
PT (2) PT1779862E (enExample)
SG (1) SG177004A1 (enExample)
SI (2) SI1526867T1 (enExample)
UA (2) UA85997C2 (enExample)
WO (1) WO2004012759A2 (enExample)
ZA (1) ZA200500726B (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
JP4855253B2 (ja) * 2003-07-29 2012-01-18 ドムペ・ファ．ル．マ・ソチエタ・ペル・アツィオーニ 幹細胞動員に有用な医薬の組み合わせ
PT1699915E (pt) * 2003-12-30 2010-08-31 Augustinus Bader Utilização de eritropoietina para a regeneração de tecido hepático
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden
RU2414236C2 (ru) 2004-12-06 2011-03-20 Зе Риджентс Оф Зи Юнивесити Оф Кэлифонье Способ улучшения структуры и/или функций артериол
AR053416A1 (es) 2005-11-10 2007-05-09 Protech Pharma S A Combinacion de glicoisoformas para el tratamiento o prevencion de la septicemia, linea celular transgenica productora de glicoformas de eritropoyetina, composicion farmaceutica que comprende a dicha combinacion, procedimientos para obtener la linea celular, procedimiento para producir dicha combinac
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EA201692543A1 (ru) 2005-11-23 2017-08-31 Акселерон Фарма Инк. Антагонисты активина-actriia и их применение для стимулирования роста кости
CA2654154A1 (en) * 2006-06-07 2007-12-13 The University Of Tokushima Treatment of ischemic diseases using erythropoietin
CN101801403A (zh) * 2006-09-29 2010-08-11 森托科尔奥索生物科技公司 用于防止、治疗葡萄糖耐受不良相关病症的人epo受体激动剂、组合物、方法及应用
US8975374B2 (en) * 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
US20100061933A1 (en) * 2006-10-20 2010-03-11 Naoki Kimura Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
WO2008047914A1 (fr) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
JP2010515736A (ja) * 2007-01-10 2010-05-13 エジソン ファーマシューティカルズ， インコーポレイテッド エリスロポイエチン活性またはトロンボポイエチン活性を有する化合物を用いる呼吸鎖障害の治療
TWI782836B (zh) 2007-02-02 2022-11-01 美商艾瑟勒朗法瑪公司 衍生自ActRIIB的變體與其用途
AR065613A1 (es) * 2007-03-09 2009-06-17 Chugai Pharmaceutical Co Ltd Agentes de proteccion para organos transplantados
EP2192907B1 (en) 2007-08-16 2018-04-18 Remedor Biomed Ltd. Erythropoietin and fibronectin compositions for therapeutic applications
CA2724841A1 (en) * 2008-05-22 2009-11-26 Edison Pharmaceuticals, Inc. Treatment of mitochondrial diseases with an erythropoietin mimetic
JP5922928B2 (ja) 2008-08-14 2016-05-24 アクセルロン ファーマ， インコーポレイテッド 赤血球レベルを高めるためのｇｄｆトラップの使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
CN102482339B (zh) 2009-06-08 2015-06-17 阿塞勒隆制药公司 用于增加产热脂肪细胞的方法
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
ES2796121T3 (es) * 2009-08-13 2020-11-25 Acceleron Pharma Inc Uso combinado de trampas de GDF y activadores del receptor de la eritropoyetina para aumentar los niveles de glóbulos rojos
ES2658292T3 (es) 2009-11-17 2018-03-09 Acceleron Pharma, Inc. Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
WO2012003960A1 (en) 2010-07-06 2012-01-12 Augustinus Bader Topical application of erythropoietin for the treatment of eye disorders and injuries
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
MX366336B (es) 2012-11-02 2019-07-05 Celgene Corp Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
CN110075355A (zh) * 2013-10-22 2019-08-02 康斯瓦维有限责任公司 用于抑制支架型心瓣膜或生物假体的狭窄、阻塞或钙化的方法
AU2015274277B2 (en) 2014-06-13 2021-03-18 Acceleron Pharma, Inc. Methods and compositions for treating ulcers
EP3543339A1 (en) 2015-02-13 2019-09-25 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN105233256A (zh) * 2015-10-28 2016-01-13 中国人民解放军第三军医大学 促红细胞生成素及其衍生物在制备治疗疾病中促进凋亡细胞清除的药物中的应用
US11534466B2 (en) * 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
GB2550114A (en) * 2016-05-03 2017-11-15 Kymab Ltd Methods, regimens, combinations & antagonists
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
CN108114282B (zh) * 2016-11-28 2021-03-02 北京大学第三医院 他汀类化合物治疗缺血性疾病的用途
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
EP3698808B1 (en) * 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
RU2695334C1 (ru) * 2018-09-25 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек карбамилированным дарбэпоэтином в эксперименте
RU2678768C1 (ru) * 2018-09-25 2019-02-01 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек карбамилированным дарбэпоэтином в эксперименте
WO2021003462A1 (en) 2019-07-03 2021-01-07 Factor Bioscience Inc. Cationic lipids and uses thereof
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN119080909A (zh) * 2024-08-29 2024-12-06 深圳赛保尔生物药业有限公司 负载peg-epo及间充质干细胞的组合物、药物及其制备方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4732889A (en) 1985-02-06 1988-03-22 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
ATE79761T1 (de) 1985-11-27 1992-09-15 Genetics Inst Behandlung einer krankheit vom aids-typ.
US5198417A (en) * 1985-11-27 1993-03-30 Genetics Institute, Inc. Methods of treating pancytopenia and AIDS by co-administering EPO and colony stimulating factors
DK173067B1 (da) 1986-06-27 1999-12-13 Univ Washington Humant erythropoietin-gen, fremgangsmåde til ekspression deraf i transficerede cellelinier, de transficerede cellelinier sa
US5013718A (en) 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU4072189A (en) 1988-02-24 1989-09-22 American National Red Cross, The Device for site directed neovascularization and method for same
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
DE4014654A1 (de) 1990-05-08 1991-11-14 Behringwerke Ag Galenische waessrige formulierungen von erythropoietin und ihre verwendung
DE69231946T2 (de) * 1991-03-11 2002-04-04 Curis, Inc. Protein-induzierende morphogenese
US5354934A (en) * 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
KR960701650A (ko) 1993-04-29 1996-03-28 찰스 엠. 브룩 에리트로포이에틴 유사체 조성물 및 방법(Eythropoietin analog compositions and methods)
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
JPH08205860A (ja) * 1994-01-21 1996-08-13 Usa Government 造血細胞の膨大化および移植方法
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
WO1996014081A1 (en) 1994-11-03 1996-05-17 Boehringer Mannheim Gmbh Use of erythropoietin in the treatment of rheumatoid arthritis
US5837675A (en) * 1995-02-03 1998-11-17 Brox; Alan G. Synergistic effect of insulin-like growth factor-I and erythropoietin
US20020052309A1 (en) * 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6284260B1 (en) 1998-02-04 2001-09-04 Veronica L. Zaharia Czeizler Treatment with erythropoietin of bleeding from benign and malignant lesions with normal and abnormal coagulation parameters
US6274158B1 (en) * 1998-02-04 2001-08-14 Veronica L. Zaharia Czeizler Treatment with recombinant human erythropoietin of bleeding in patients with normal and abnormal hemostasis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
PL352223A1 (en) * 1999-04-13 2003-08-11 Kenneth S Warren Inst Modulation of excitable tissue function by peripherally administered erythropoietin
EP1286691B1 (en) 2000-05-02 2007-11-14 Action Pharma A/S Methods for treatment of diseases associated with acute inflammation under non-ischemic conditions
US7259146B2 (en) * 2000-05-26 2007-08-21 Ortho-Mcneil Pharmaceutical, Inc. Neuroprotective peptides
US7078376B1 (en) * 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
US20020065214A1 (en) * 2000-11-29 2002-05-30 Adrian Iaina Method of treating congestive heart failure
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
DE60232870D1 (de) * 2001-04-04 2009-08-20 Genodyssee Neue polynukleotide und polypeptide des erythropoietingens
US6784154B2 (en) * 2001-11-01 2004-08-31 University Of Utah Research Foundation Method of use of erythropoietin to treat ischemic acute renal failure
BR0214557A (pt) * 2001-11-28 2006-06-06 Ortho Mcneil Pharm Inc regime de dosagem de eritropoietina para o tratamento de anemia
ATE359087T1 (de) * 2002-01-09 2007-05-15 Crucell Holland Bv Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen
US6748154B2 (en) * 2002-03-28 2004-06-08 Nortel Networks Limited Optical module access tray
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
DE102004004509B4 (de) * 2004-01-23 2010-07-01 Epoplus Gmbh Co.Kg Einsatz von niedrig dosiertem Erythropoietin zur Stimulation endothelialer Vorläuferzellen sowie zur Organregeneration und Progressionsverlangsamung von Endorganschäden

Also Published As

Publication number Publication date
JP2010280670A (ja) 2010-12-16
NO20051002L (no) 2005-04-18
CN101099731B (zh) 2011-02-16
IS7633A (is) 2005-01-06
AU2009200748A1 (en) 2009-03-19
HK1108625A1 (zh) 2008-05-16
JP2006503001A (ja) 2006-01-26
JP4727988B2 (ja) 2011-07-20
CN101099860B (zh) 2011-06-01
MXPA05001120A (es) 2005-08-03
DK1526867T3 (da) 2007-09-17
IS8817A (is) 2009-05-06
WO2004012759B1 (de) 2004-07-08
KR20050026513A (ko) 2005-03-15
SI1526867T1 (sl) 2007-10-31
KR20100077033A (ko) 2010-07-06
PL395151A1 (pl) 2011-08-16
ATE468132T1 (de) 2010-06-15
CA2493598A1 (en) 2004-02-12
AU2003255290B2 (en) 2009-04-09
EA013966B1 (ru) 2010-08-30
IL204577A (en) 2012-08-30
IS2671B (is) 2010-09-15
IS8909A (is) 2010-07-02
SI1779862T1 (sl) 2010-09-30
US20050272634A1 (en) 2005-12-08
UA94913C2 (ru) 2011-06-25
ATE360436T1 (de) 2007-05-15
EA200700196A1 (ru) 2007-04-27
EP1526867B1 (de) 2007-04-25
WO2004012759A3 (de) 2004-06-03
CY1108052T1 (el) 2013-09-04
DE10234192B4 (de) 2009-11-26
CN1681526A (zh) 2005-10-12
DE50312729D1 (de) 2010-07-01
EA009463B1 (ru) 2007-12-28
CY1110713T1 (el) 2015-06-10
JP2010280672A (ja) 2010-12-16
EA200500281A1 (ru) 2005-06-30
EP1779862A1 (de) 2007-05-02
EP1526867A2 (de) 2005-05-04
DK1779862T3 (da) 2010-08-16
PT1779862E (pt) 2010-08-18
US20100247450A1 (en) 2010-09-30
US20100247451A1 (en) 2010-09-30
JP2010280671A (ja) 2010-12-16
WO2004012759A2 (de) 2004-02-12
EA200801236A1 (ru) 2009-02-27
HRP20070189A2 (en) 2007-07-31
HK1081841A1 (en) 2006-05-26
IL166401A0 (en) 2006-01-15
UA85997C2 (en) 2009-03-25
ES2285195T3 (es) 2007-11-16
HRP20100187A2 (hr) 2010-08-31
ES2345673T3 (es) 2010-09-29
US7745387B2 (en) 2010-06-29
HRP20050065A2 (en) 2005-10-31
EP1779862B1 (de) 2010-05-19
SG177004A1 (en) 2012-01-30
PT1526867E (pt) 2007-07-09
CN101099860A (zh) 2008-01-09
US20100247452A1 (en) 2010-09-30
DE50307140D1 (en) 2007-06-06
BR0312981A (pt) 2005-06-14
CN101099731A (zh) 2008-01-09
AU2003255290A1 (en) 2004-02-23
EP2191838A1 (de) 2010-06-02
DE10234192A1 (de) 2004-02-12
CA2710100A1 (en) 2004-02-12
PL374874A1 (en) 2005-11-14

Similar Documents

Publication Publication Date Title
DE50307140D1 (en) Erythropoietin in subpolycythämischen dosen
Yu et al. Effects of photostimulation on wound healing in diabetic mice
DE3880318D1 (de) Polypeptide mit kollagen typ iv aktivitaet.
BR9907273A (pt) Prótese, artigo, válvura cardìaca protética, e, processos para produzir uma prótese para um paciente humano, para modificar um substrato, para associar células endoteliais com um substrato, para distribuir um artigos médico para uso por profissionais de cuidados com a saúde, e para produzir um material biocompatìvel
Lee et al. Avulsion of a tricuspid valve leaflet during traction on an infected, entrapped endocardial pacemaker electrode: the role of electrode design
CA2467797A1 (en) Increased biocompatibility of implantable medical devices
US20100261957A1 (en) Cardiac wall tension relief with cell loss management
WO2003076604A3 (en) Surgical device for skin therapy or testing
PL2233150T3 (pl) Erytropoetyna do zastosowania w leczeniu ran lub transplantacji komórek
EP0308802A2 (en) Composition for preventing and treating thrombosis, and hemocompatible surgical implant therefor
ES2162331T3 (es) Utilizacion del factor de crecimiento del tejido nervioso para conservacion, cultivo o tratamiento de la cornea.
CA2073453A1 (en) Methods of enhancing wound healing and tissue repair
Ko et al. Durability of prefabricated versus normal random flaps against a bacterial challenge
Kimura et al. Coronary artery bypass grafting and aortic valve replacement in a patient with a tracheostoma
Lozano et al. A comparative study of the early vascularization of porous carbon and bone as a graft
Senges et al. Effect of brief periods of paced ventricular tachycardia on coronary blood flow in dogs before and after graded coronary stenosis
Yamaguchi et al. Skin grafting: surgical techniques
Sanchez Cultivo in vitro de epidermis.
Laing et al. Skin replacement after burn injury
WO2004037120A3 (en) Implantable medical devices using zinc
Zhao et al. Bioactive materials in the circulatory system
RU93037867A (ru) Способ лечения длительно незаживающих ран и трофических язв кожных покровов
IL118968A (en) Apparatus for biostimulation of myocardial tissue by electromagnetic wave radiation